The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Proposed Mechanism of Action

Ozanimod is an oral, sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P₁) and 5 (S1P₅). The exact mechanism by which ozanimod exerts its therapeutic action is unknown. Preclinical data showed that ozanimod was able to induce internalization of the S1P₁ receptor and decrease circulation of pro-inflammatory lymphocytes in the bloodstream. A reduction in circulating pro-inflammatory lymphocytes may prevent their migration to sites of inflammation. Preclinical data have also demonstrated that ozanimod treatment results in a dose-dependent reduction in key lymphocyte populations that play a role in inflammatory bowel disease (IBD).¹ These results may support the hypothesis that S1P₁ is a potential new target for IBD treatment.

Ozanimod Proposed Mechanism of Action

GI, gastrointestinal; S1P, sphingosine-1-phosphate

Ozanimod, an S1P₁ and S1P₅ ?modulator is hypothesized to prevent migration of lymphocytes from the lymphoid tissue to the gastrointestinal tract¹